MAP4K1 and neoplasm: A recent study demonstrated that mice containing a germline mutation in HPK1 that abolishes its kinase activity and harboring an implanted tumor, exhibited an enhanced response to anti-PD-L1 immunotherapy as compared to tumor bearing wild type mice, suggesting that inhibition of HPK1 in T lymphocytes may potentiate the activity of checkpoint inhibitors [16, 27].